Step 1 Endocrine
Endocrine is one of the highest-yield areas on USMLE Step 1, covering the HPA, HPT, and HPG axes; pituitary, thyroid, parathyroid, and adrenal pathology; pancreatic endocrine tumors; and the pharmacology threading through all of it. Questions range from pure physiology — why pulsatile GnRH suppresses rather than stimulates — to clinical vignettes asking you to sequence a workup for Cushing syndrome or choose the right insulin for a T1DM patient in DKA. If you are looking for high-yield endocrine topics for Step 1, axis logic and diagnostic sequencing are the two skills that separate strong scores from average ones.
The exam loves axis logic: a low TSH means hyperthyroidism only if the axis is intact — central hypothyroidism breaks that rule. Students consistently assume low TSH always equals hyperthyroidism, missing the central hypothyroidism cases where both TSH and T4 are low. It tests diagnostic sequences (confirm cortisol excess before measuring ACTH, not after), distinguishes primary from secondary or tertiary disease by reading labs together, and rewards knowing when two things look similar but require opposite management (SIADH vs DI, DKA vs HHS, methimazole vs PTU by trimester).
What makes USMLE endocrine questions hard is the density of overlapping hormone patterns and the multi-step reasoning required. Getting hyperpigmentation wrong — thinking cortisol drives it when it is actually ACTH — costs points across Addison, Cushing, and CAH questions. Pharmacology traps are everywhere in Step 1 endocrine pharmacology: bisphosphonates are anti-resorptive, not anabolic; metformin is a sensitizer, not a secretagogue; PTU precedes iodine in thyroid storm. Build the logic of each axis first, then layer the pathology on top.
Hypothalamic-Pituitary-Adrenal (HPA) Axis
Cortisol feedback hits both hypothalamus and pituitary; chronic steroids suppress this axis, demanding a taper.
- Confuses cortisol negative feedback as pituitary-only rather than acting at both hypothalamus and pituitary
- Reverses the cortisol diurnal rhythm, placing the peak in the evening instead of early morning
Hypothalamic-Pituitary-Thyroid (HPT) Axis
TRH excess in hypothyroidism can stimulate prolactin, and most circulating T3 comes from peripheral T4 deiodination.
- Interprets low TSH as always indicating hyperthyroidism, missing central hypothyroidism
- Attributes hyperprolactinemia in hypothyroidism to a prolactinoma rather than TRH-driven lactotroph stimulation
Hypothalamic-Pituitary-Gonadal (HPG) Axis
Pulsatile GnRH stimulates LH/FSH; continuous delivery downregulates receptors — and estrogen drives a positive feedback LH surge at ovulation.
- Confuses continuous GnRH agonist administration as stimulatory rather than suppressive due to receptor downregulation
- Attributes prolactin-induced hypogonadism to direct gonadal suppression rather than GnRH inhibition at the hypothalamus
Hormone Signaling (Peptide vs Steroid)
Steroid hormones act at intracellular receptors with transcription-dependent delays; peptide hormones use surface receptors and second messengers.
- Places steroid hormone receptors on the cell surface rather than intracellularly
- Assumes steroid hormones act rapidly, not recognizing the transcription-dependent delay in their mechanism
Prolactinoma
Dopamine agonists are first-line, not surgery; men present late with mass effects rather than galactorrhea-amenorrhea.
- Selects surgery as first-line for prolactinoma instead of dopamine agonist therapy
- Misses that men with prolactinoma present later with mass effects rather than the galactorrhea-amenorrhea seen in women
Acromegaly / Gigantism (GH-Secreting Adenoma)
IGF-1 screens; OGTT-GH suppression confirms; cardiovascular disease — not colon cancer — is the leading cause of death.
- Uses random GH rather than IGF-1 as the screening test for acromegaly
- Stops at elevated IGF-1 for diagnosis without recognizing the OGTT-GH suppression test as the confirmatory step
Cushing Disease (ACTH-Secreting Pituitary Adenoma)
Confirm cortisol excess first, then measure ACTH, then localize — petrosal sinus sampling resolves pituitary versus ectopic ACTH.
- Conflates Cushing disease (pituitary ACTH adenoma) with Cushing syndrome (any cause of cortisol excess)
- Jumps to ACTH measurement before confirming cortisol excess, reversing the correct stepwise workup
SIADH (Syndrome of Inappropriate ADH)
Euvolemic hyponatremia with inappropriately concentrated urine; rapid correction risks osmotic demyelination syndrome.
- Expects dilute urine in SIADH rather than inappropriately concentrated urine
- Advocates rapid sodium correction in SIADH without recognizing the risk of osmotic demyelination syndrome
Diabetes Insipidus (Central vs Nephrogenic)
Water deprivation distinguishes DI from psychogenic polydipsia; desmopressin challenge then separates central from nephrogenic.
- Applies desmopressin as treatment for nephrogenic DI, not recognizing that the kidney is unresponsive to ADH in that subtype
- Stops at water deprivation without adding desmopressin challenge, missing the step that distinguishes central from nephrogenic DI
Hypopituitarism (Sheehan, Empty Sella, Panhypopituitarism)
Glucocorticoid replacement must precede thyroid hormone; failure to lactate is the earliest sign of Sheehan syndrome.
- Replaces thyroid hormone before glucocorticoid in panhypopituitarism, risking precipitation of adrenal crisis
- Identifies amenorrhea rather than failure to lactate as the earliest sign of Sheehan syndrome
Graves Disease
TSI activates — not blocks — the TSH receptor; ophthalmopathy is autoantibody-mediated, not caused by thyroid hormone excess.
- Confuses TSI as a blocking antibody rather than an activating agonist at the TSH receptor
- Misclassifies Graves as Type III rather than Type II hypersensitivity
Toxic Multinodular Goiter and Toxic Adenoma
Autonomously functioning nodules have constitutively active TSH receptors and show focal hot uptake unlike Graves' diffuse pattern.
- Confuses the focal hot nodule RAIU pattern of toxic adenoma with the diffuse uptake of Graves disease
- Misses that autonomous nodule function is TSH-independent due to constitutively activating mutations
Thyroiditis (de Quervain, Silent, Hashimoto, Riedel)
Low RAIU during the hyperthyroid phase distinguishes all thyroiditis subtypes from Graves and toxic nodular disease.
- Expects high RAIU in de Quervain thyroiditis hyperthyroid phase rather than characteristically low uptake
- Confuses painful de Quervain thyroiditis with painless silent/postpartum thyroiditis
Hypothyroidism (Primary, Cretinism, Drug-Induced)
Iodine deficiency leads globally; cretinism follows; TSH takes 6–8 weeks to normalize after levothyroxine starts.
- Interprets low TSH as hyperthyroidism without considering central hypothyroidism when free T4 is also low
- Attributes cretinism to genetic causes rather than recognizing iodine deficiency as the leading global etiology
Thyroid Emergencies (Storm and Myxedema Coma)
PTU must precede iodine in thyroid storm; empiric steroids are required in myxedema coma to cover possible adrenal insufficiency.
- Reverses the order of PTU and iodine in thyroid storm treatment, not recognizing that PTU must precede iodine
- Attributes the benefit of beta-blockers in thyroid storm to reduced hormone synthesis rather than adrenergic blockade and peripheral T4-to-T3 conversion inhibition
Thyroid Cancers (Papillary, Follicular, Medullary, Anaplastic)
Papillary spreads lymphatically; follicular diagnosis requires surgical histology for capsular invasion; medullary markers are calcitonin and CEA.
- Misattributes papillary thyroid carcinoma's spread to hematogenous rather than lymphatic routes
- Expects FNAB to diagnose follicular carcinoma, missing that capsular/vascular invasion requires surgical histology
Hyperparathyroidism (Primary, Secondary, Tertiary)
Solitary adenoma causes most primary cases; expect high calcium, low phosphate — tertiary disease unlike secondary has autonomous hypercalcemia.
- Expects high phosphate in primary hyperparathyroidism rather than the characteristic hypophosphatemia from PTH-driven phosphaturia
- Fails to distinguish the calcium levels of secondary (low/normal Ca) versus tertiary (high Ca) hyperparathyroidism
Hypoparathyroidism and Pseudohypoparathyroidism
Pseudohypoparathyroidism shows high PTH with end-organ resistance; hypomagnesemia blocks PTH secretion and must be corrected first.
- Confuses the PTH level in pseudohypoparathyroidism (high) with that of true hypoparathyroidism (low)
- Misidentifies Chvostek as the more specific sign of hypocalcemia rather than Trousseau
Osteoporosis
T-score at or below −2.5 defines osteoporosis; bisphosphonates carry specific risks of atypical femur fracture and osteonecrosis of the jaw.
- Misremembers the T-score cutoff for osteoporosis, confusing osteopenia and osteoporosis thresholds
- Reverses the bone type and fracture pattern of postmenopausal versus senile osteoporosis
Osteomalacia and Rickets
Defective mineralization from vitamin D deficiency produces low calcium, low phosphate, and high ALP — labs that are normal in osteoporosis.
- Fails to distinguish the abnormal labs of osteomalacia (low Ca, low PO4, high ALP) from the normal labs of osteoporosis
- Conflates the age-specific skeletal manifestations of rickets (open growth plates) with osteomalacia (pseudofractures in adults)
Paget Disease of Bone
Disordered remodeling elevates ALP in isolation; hypervascular bone drives high-output heart failure, and sarcomatous transformation is the feared complication.
- Confuses Paget's isolated ALP elevation with the hypercalcemia seen in hyperparathyroidism
- Confuses Paget disease with a primary bone tumor rather than a remodeling disorder with distinct phases
Cushing Syndrome (All Causes)
Screen for cortisol excess before anything else; hyperpigmentation signals high ACTH, pointing away from adrenal adenoma.
- Skips the screening step and jumps to ACTH measurement before confirming hypercortisolism
- Confuses the dexamethasone suppression response of ectopic ACTH tumors with that of pituitary adenomas
Adrenal Insufficiency (Addison, Secondary, Crisis)
Primary adrenal insufficiency causes hyperkalemia and hyperpigmentation via ACTH; secondary insufficiency spares aldosterone and pigmentation.
- Applies hyperkalemia to secondary adrenal insufficiency, which lacks aldosterone deficiency
- Attributes hyperpigmentation to cortisol deficiency rather than elevated ACTH/alpha-MSH from POMC
Congenital Adrenal Hyperplasia (CAH)
21-hydroxylase deficiency causes salt-wasting and virilization; 11-beta deficiency adds hypertension; 17-alpha deficiency blocks sex steroids causing sexual infantilism.
- Attributes salt-wasting in 21-hydroxylase deficiency to cortisol deficiency rather than aldosterone deficiency
- Confuses the blood pressure phenotype of 11beta-hydroxylase deficiency with the hypotension of 21-hydroxylase deficiency
Pheochromocytoma and Paraganglioma
Alpha blockade before beta blockade is mandatory preoperatively; plasma/urine metanephrines outperform catecholamines for diagnosis.
- Reverses the required sequence of alpha-then-beta blockade in pheochromocytoma preoperative management
- Selects serum catecholamines over plasma/urine metanephrines as the preferred diagnostic test for pheo
Neuroblastoma
Children under five with a midline-crossing abdominal mass, elevated urinary HVA/VMA, and MYCN amplification define this adrenal medulla tumor.
- Attributes midline-crossing abdominal mass in a child to Wilms tumor rather than neuroblastoma
- Fails to distinguish the predominant urinary metabolite pattern of neuroblastoma (HVA) from pheochromocytoma (VMA)
Hyperaldosteronism (Conn Syndrome)
Suppressed renin with elevated aldosterone defines primary disease; bilateral hyperplasia is managed medically, not surgically.
- Predicts elevated renin in primary hyperaldosteronism rather than the suppressed renin that defines it
- Attributes metabolic alkalosis in hyperaldosteronism solely to hypokalemia rather than direct renal H+ excretion
Type 1 Diabetes Mellitus
Autoimmune CD8+ T-cell beta-cell destruction; C-peptide is low regardless of exogenous insulin; HLA-DR3/DR4 confers risk.
- Attributes T1DM beta-cell destruction to CD4+ T cells rather than CD8+ cytotoxic T cells
- Expects elevated C-peptide in T1DM patients on insulin therapy, not recognizing C-peptide reflects only endogenous insulin secretion
Type 2 Diabetes Mellitus
Early disease features compensatory hyperinsulinemia; HbA1c ≥6.5% diagnoses diabetes; SGLT2i and GLP-1 agonists reduce cardiovascular mortality.
- Assumes low insulin is present at T2DM onset rather than the compensatory hyperinsulinemia of early disease
- Misremembers the HbA1c diagnostic cutoff for diabetes as below 6.5%
MODY (Maturity-Onset Diabetes of the Young)
Autosomal dominant single-gene diabetes in young non-obese patients; HNF1A-MODY responds to sulfonylureas, GCK-MODY needs no treatment.
- Misclassifies MODY inheritance as autosomal recessive rather than autosomal dominant
- Defaults to insulin therapy for MODY rather than recognizing sulfonylurea responsiveness in HNF1A-MODY
Diabetic Ketoacidosis (DKA)
Glucagon-driven lipolysis — not hyperglycemia itself — produces ketones; potassium must be repleted before insulin is started.
- Chooses bicarb over K repletion when serum K is 3.1 in DKA, missing the K-before-insulin rule
- Assumes bicarbonate is a standard early DKA treatment rather than a rarely-used last resort
Hyperosmolar Hyperglycemic State (HHS)
Residual insulin in T2DM prevents ketosis despite extreme hyperglycemia; aggressive volume repletion precedes insulin in management.
- Assumes HHS involves complete insulin deficiency like DKA, missing the role of residual insulin in preventing ketosis
- Prioritizes insulin over volume repletion in HHS, reversing the correct treatment hierarchy
Chronic Complications of Diabetes
Cardiovascular disease kills most diabetics; microvascular pericyte loss drives retinopathy via VEGF, and glomerular pathology defines nephropathy.
- Attributes diabetic nephropathy to macrovascular renal artery disease rather than glomerular microvascular pathology
- Attributes proliferative retinopathy to direct ganglion cell glycosylation rather than the pericyte loss → ischemia → VEGF sequence
Insulinoma
Whipple triad plus elevated C-peptide and insulin on a 72-hour fast distinguishes endogenous insulin excess from exogenous administration.
- Forgets that C-peptide is co-secreted with endogenous insulin, so insulinoma raises both while exogenous insulin suppresses C-peptide
- Missing the three components of Whipple triad required to diagnose insulinoma clinically
Glucagonoma
Necrolytic migratory erythema is the hallmark rash; glucagon excess causes hyperglycemia, not hypoglycemia.
- Confuses glucagonoma with insulinoma by expecting hypoglycemia rather than hyperglycemia from glucagon excess
- Missing that necrolytic migratory erythema is the hallmark dermatologic manifestation of glucagonoma
VIPoma (Verner-Morrison Syndrome)
Watery diarrhea, hypokalemia, and achlorhydria define Verner-Morrison syndrome because VIP inhibits gastric acid secretion.
- Confuses VIPoma secretory diarrhea mechanism with osmotic or serotonin-mediated diarrhea
- Missing that achlorhydria (not hyperchlorhydria) is part of the VIPoma triad because VIP inhibits gastric acid
Gastrinoma (Zollinger-Ellison Syndrome)
Refractory peptic ulcers, diarrhea, and a paradoxical gastrin rise after secretin localize gastrinoma — the most common pancreatic tumor in MEN1.
- Attributes ZES diarrhea to a direct VIP-like secretagogue effect rather than to acid-mediated mucosal and enzymatic damage
- Missing that gastrinoma is the most common pancreatic islet tumor in MEN1 and localizes to the gastrinoma triangle
Somatostatinoma
Broad inhibitory hormone effects produce a triad of diabetes, steatorrhea, and gallstones.
- Confuses the therapeutic use of somatostatin analogs with the pathologic excess of somatostatin in somatostatinoma
- Missing the classic inhibitory triad of somatostatinoma: diabetes, steatorrhea, and gallstones
Multiple Endocrine Neoplasia Type 1 (MEN1)
Parathyroid hyperplasia is the most common manifestation; menin tumor suppressor on chromosome 11 is mutated — not RET.
- Incorrectly includes medullary thyroid carcinoma in MEN1 instead of correctly placing it in MEN2
- Names pituitary adenoma as the most common MEN1 manifestation rather than hyperparathyroidism
Multiple Endocrine Neoplasia Types 2A and 2B
RET gain-of-function causes medullary thyroid carcinoma in both MEN2A and 2B; MEN2B substitutes mucosal neuromas for hyperparathyroidism.
- Conflates MEN2A and MEN2B, missing that MEN2B has mucosal neuromas/marfanoid habitus instead of hyperparathyroidism
- Confuses MEN2 RET gain-of-function oncogene mutation with the loss-of-function tumor suppressor mechanism of MEN1
Carcinoid Tumor and Carcinoid Syndrome
Hepatic metastases are required for carcinoid syndrome; tryptophan diversion to serotonin causes niacin deficiency, not direct serotonin toxicity.
- Misses that tryptophan diversion—not serotonin excess per se—causes niacin deficiency in carcinoid syndrome
- Confuses carcinoid tumor presence with carcinoid syndrome, missing the requirement for hepatic metastases or extra-portal primary
Insulin Preparations (Rapid, Short, Intermediate, Long)
Long-acting insulins are peakless; NPH has a peak; insulin drives potassium intracellularly rather than excreting it renally.
- Confuses long-acting insulin (peakless) with intermediate-acting NPH (has a peak), increasing hypoglycemia risk misattribution
- Misattributes insulin-induced hypokalemia to renal excretion rather than intracellular potassium shift
Sulfonylureas and Meglitinides
K-ATP channel closure releases insulin independent of glucose; first-generation agents cause a disulfiram-like reaction and broader drug interactions.
- Confuses sulfonylurea-driven insulin release (glucose-independent) with physiologic glucose-stimulated secretion
- Conflates meglitinides with sulfonylureas, missing their shorter duration and postprandial-specific utility
Metformin
AMPK activation suppresses hepatic gluconeogenesis without stimulating insulin secretion; lactic acidosis reflects impaired hepatic lactate clearance.
- Confuses metformin's mechanism (AMPK/hepatic gluconeogenesis) with acarbose's mechanism (intestinal glucose absorption blockade)
- Misattributes metformin-induced lactic acidosis to increased lactate production rather than impaired hepatic lactate clearance
Thiazolidinediones (TZDs)
PPAR-gamma agonism sensitizes adipose to insulin but causes fluid retention, heart failure risk, and fractures through osteoblast suppression.
- Confuses TZD mechanism (PPAR-gamma insulin sensitization in adipose) with pancreatic insulin secretagogue action
- Misattributes TZD-induced fluid retention to nephrotoxicity rather than renal sodium retention via PPAR-gamma
GLP-1 Agonists and DPP-4 Inhibitors
GLP-1 agonists achieve supraphysiologic stimulation with weight loss and nausea; DPP-4 inhibitors are weight-neutral and lack their cardiovascular mortality benefit.
- Conflates GLP-1 agonists (supraphysiologic stimulation, weight loss, nausea) with DPP-4 inhibitors (modest endogenous GLP-1 elevation, weight-neutral)
- Incorrectly attributes GLP-1 agonist cardiovascular mortality benefit to DPP-4 inhibitors
SGLT2 Inhibitors
Blocking proximal tubule glucose reabsorption causes euglycemic DKA, genital mycotic infections, and glucose-independent cardiovascular and renal protection.
- Misses that SGLT2 inhibitor-associated DKA can be euglycemic, leading to delayed diagnosis
- Attributes SGLT2 inhibitor heart failure benefit to glucose lowering alone, missing glucose-independent cardioprotective mechanisms
Alpha-Glucosidase Inhibitors and Others
Alpha-glucosidase inhibition blunts postprandial glucose; hypoglycemia reversal requires monosaccharide glucose because disaccharide absorption is blocked.
- Misses that acarbose-associated hypoglycemia requires monosaccharide glucose (not sucrose) because acarbose blocks disaccharide digestion
- Misses that acarbose's GI side effects result from colonic bacterial fermentation of unabsorbed carbohydrates
Thyroid Pharmacotherapy (Levothyroxine, Methimazole, PTU, Iodine)
PTU is preferred in the first trimester and in thyroid storm because it also blocks peripheral T4-to-T3 conversion; agranulocytosis can occur with either antithyroid drug.
- Confuses trimester-specific antithyroid drug preference: PTU in first trimester (teratogenicity of methimazole), methimazole thereafter (hepatotoxicity of PTU)
- Misses PTU's additional mechanism of blocking peripheral T4-to-T3 conversion, which is why it is preferred in thyroid storm
Osteoporosis Pharmacotherapy
Bisphosphonates inhibit osteoclasts; teriparatide is anabolic via intermittent PTH; denosumab discontinuation requires bridging to a bisphosphonate to prevent rebound fracture.
- Confuses bisphosphonate mechanism (anti-resorptive via osteoclast inhibition) with anabolic bone formation
- Confuses intermittent PTH dosing (anabolic, teriparatide) with continuous PTH elevation (catabolic, as in hyperparathyroidism)
Cushing-Directed Pharmacotherapy
Ketoconazole inhibits adrenal steroidogenesis; mifepristone blocks the glucocorticoid receptor; pasireotide acts upstream at pituitary somatostatin receptors.
- Fails to recognize ketoconazole as an adrenal steroidogenesis inhibitor in Cushing pharmacotherapy
- Confuses mifepristone's receptor antagonism with adrenal synthesis inhibition
Acromegaly Pharmacotherapy
Somatostatin analogs suppress pituitary GH; pegvisomant blocks the GH receptor peripherally without affecting GH secretion.
- Confuses pegvisomant's receptor antagonism with pituitary GH suppression
- Confuses octreotide's upstream pituitary mechanism with direct GH receptor blockade
Pharmacologic Management of Diabetes Insipidus
Desmopressin selectively activates V2 receptors and treats central DI, hemophilia A, and vWD — but the kidney cannot respond in nephrogenic DI.
- Confuses desmopressin's selective V2 agonism with the mixed V1/V2 activity of native ADH
- Unaware that desmopressin is used for von Willebrand disease and hemophilia A in addition to central DI
See how your Anki deck covers Endocrine.
Upload your deck for a free audit →